Midday Report: Pacific of California (PACB) Trades Higher June 21

Equities Staff  |

Pacific Biosciences of California Inc (NASDAQ: PACB) shares moved 9.20%, or $0.39 per share, as on 12:04:52 est today. Since opening the day at $4.40, 2,961,995 shares of Pacific of California have been traded today and the stock has moved between $4.64 and $4.36.  

Already the company has a YTD change of 79.28%.

Pacific of California anticipates its next earnings on 2022-08-03.

For technical charts, analysis, and more on Pacific of California visit the company profile.

About Pacific Biosciences of California Inc

Pacific Biosciences of California, Inc. is empowering life scientists with highly accurate long-read sequencing. The company's innovative instruments are based on Single Molecule, Real-Time (SMRT®) Sequencing technology, which delivers a comprehensive view of genomes, transcriptomes, and epigenomes, enabling access to the full spectrum of genetic variation in any organism. Cited in thousands of peer-reviewed publications, PacBio® sequencing systems are in use by scientists around the world to drive discovery in human biomedical research, plant and animal sciences, and microbiology.

To get more information on Pacific Biosciences of California Inc and to follow the company's latest updates, you can visit the company's profile page here: Pacific Biosciences of California Inc's Profile. For more news on the financial markets be sure to visit Equities News. Also, don't forget to sign-up for the Daily Fix to receive the best stories to your inbox 5 days a week.

Sources: Symbol info widget is provided by TradingView based on 15-minute-delayed prices. All other article data is provided by IEX Cloud on 15-minute delayed prices or EOD company info.

Stock price data is provided by IEX Cloud on a 15-minute delayed basis. Chart price data is provided by TradingView on a 15-minute delayed basis.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer

Trending Articles

The Best Laid Plans of Mice and Men — Part II
Why I’m Buying the 'New' Value Stocks
Investors Must Understand 5G Wireless Growth Wave: Jeff Kagan
'Goldilocks' Stocks Will Define This Decade

Market Movers

Sponsored Financial Content